---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-302608"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2026-07-14T12:30:27+00:00"
generated_at: "2026-07-14T12:35:04.603105+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Syndax unveils SNDX-4321 (allosteric EGFRi) and SNDX-62122 (menin inhibitor) at R&D event

## Summary
- SNDX-4321: novel mutant-selective allosteric EGFR inhibitor for NSCLC; IND expected by end of 2026, Phase 1 in 2027.
- SNDX-62122: first next-gen menin inhibitor from internal library; IND and Phase 1 in MF expected in 2027.
- Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26.
- Revumenib Phase 1/2 trial in MF expected to initiate in 4Q26 with initial data in H2 2027.
- Company highlights late-stage revumenib and axatilimab programs in acute leukemia and chronic GVHD.

## SEC filing metadata
- accession: 0001193125-26-302608
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2026-07-14T12:30:27+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000119312526302608/0001193125-26-302608-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000119312526302608/sndx-20260714.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-302608
- JSON: https://secwatch.observer/filing/0001193125-26-302608.json
- Plain text: https://secwatch.observer/filing/0001193125-26-302608.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.